supp.fit

Policosanol: study protocols

63 study groups say how much Policosanol participants took a day. These are the doses the studies gave. They are not a recommendation.

Policosanol: what the research found →

Dose per serving from products

256 products in our catalogue print how much Policosanol a serving holds.

Most common: 5 mg to 10 mg, 64% of 256 products.

Dose per servingProducts
2.5 mg or less
3
2.5 mg to 5 mg
20
5 mg to 10 mg
165
10 mg to 25 mg
48
25 mg to 50 mg
12
over 50 mg
8

Dose per serving from research

63 study groups in 45 studies say how much Policosanol participants took a day.

These are the doses the studies gave. They are not a recommendation.

Most common: 5 mg to 10 mg, 52% of 63 study groups.

Daily doseStudy groups
2.5 mg or less
1
2.5 mg to 5 mg
6
5 mg to 10 mg
33
10 mg to 25 mg
19
25 mg to 50 mg
4

Commonly used together

13 of 63 study groups took Policosanol with something else. Shown: what 3 or more different studies gave.

What was given together, not what works together.

Taken withStudy groups
Red Yeast Rice
9
Berberine
8
Coenzyme Q10
4
Folic Acid
4
Astaxanthin
3

63 study groups

Study
A double-blind, placebo-controlled study of the effects of policosanol in patients with intermittent claudication
1999 · policosanol · Patients with intermittent claudication; age and sex not specified
20 mg26 weeks31
A long-term study of policosanol in the treatment of intermittent claudication
2001 · policosanol · Patients with moderately severe intermittent claudication
20 mg2 years—
Effects of policosanol and lovastatin in patients with intermittent claudication: a double-blind comparative pilot study
2003 · policosanol · Patients with moderately severe intermittent claudication; age and sex not specified
10 mg20 weeks—
Effects of policosanol and ticlopidine in patients with intermittent claudication: a double-blinded pilot comparative study
2004 · policosanol · Adults with moderately severe intermittent claudication
20 mg20 weeks—
Effects of policosanol (10 mg/d) versus aspirin (100 mg/d) in patients with intermittent claudication: a 10-week, randomized, comparative study
2008 · policosanol · Patients with intermittent claudication
10 mg10 weeks—
Effects of policosanol in the functional recovery of non-cardioembolic ischemic stroke hypertensive patients
2018 · policosanol + aspirin · Hypertensive patients, mean age 66 years, with recent non-cardioembolic ischemic stroke and modified Rankin Scale score 2 to 4
20 mg26 weeks—
Efficacy and Safety of Policosanol (Sugarcane Wax Alcohols) 20 mg/Day in Cuban Prehypertensive Patients: A Randomized, Double-Blind, Multicentre Study
2025 · Policosanol · Women and men aged 20–60 with prehypertension and 0–2 cardiovascular risk factors
20 mg12 weeks100
Policosanol (sugarcane wax alcohols) 20 mg/day in Cuban Patients With Grade I Hypertension: A Randomized, Double-Blind, Multicenter Study
2025 · Policosanol · Women and men aged 20–60 years with grade I hypertension and 0–2 cardiovascular risk factors
20 mg12 weeks100
[Comparative effects of policosanol and two HMG-CoA reductase inhibitors on type II hypercholesterolemia]
1999 · policosanol · Patients with type II hypercholesterolemia and LDL cholesterol over 160 mg/dl
10 mg8 weeks55
Comparison of the efficacy, safety and tolerability of original policosanol versus other mixtures of higher aliphatic primary alcohols in patients with type II hypercholesterolemia
2002 · policosanol group, 10 mg/day step · Patients with type II hypercholesterolemia; age and sex not specified
10 mg5 weeks55
Beneficial Effect of Cuban Policosanol on Blood Pressure and Serum Lipoproteins Accompanied with Lowered Glycated Hemoglobin and Enhanced High-Density Lipoprotein Functionalities in a Randomized, Placebo-Controlled, and Double-Blinded Trial with Healthy Japanese
2023 · policosanol group · Healthy Japanese men and women aged 20–65 years with normal blood pressure and LDL-C of 120–<160 mg/dL
20 mg12 weeks36
Effects of policosanol 20 versus 40 mg/day in the treatment of patients with type II hypercholesterolemia: a 6-month double-blind study
2001 · policosanol 20 mg/day · Patients with type II hypercholesterolemia
20 mg24 weeks29
A comparison of the effects of D-003 and policosanol (5 and 10 mg/day) in patients with type II hypercholesterolemia: a randomized, double-blinded study
2005 · Policosanol 10 mg/day · Patients with type II hypercholesterolemia; age and sex not reported
10 mg8 weeks25
Effects of policosanol and lovastatin on lipid profile and lipid peroxidation in patients with dyslipidemia associated with type 2 diabetes mellitus
2002 · policosanol · Adults with dyslipidemia associated with type 2 diabetes mellitus
10 mg8 weeks18
Effects of policosanol in patients with type II hypercholesterolemia and additional coronary risk factors
1999 · Policosanol group, next 12 weeks · Patients with type II hypercholesterolemia and additional coronary risk factors
10 mg12 weeks—
Effects of policosanol and pravastatin on lipid profile, platelet aggregation and endothelemia in older hypercholesterolemic patients
1999 · policosanol · Older patients with type II hypercholesterolemia, LDL cholesterol above 3.4 mmol/l, and high coronary risk
10 mg8 weeks—
Comparative study of the efficacy and tolerability of policosanol and lovastatin in patients with hypercholesterolemia and noninsulin dependent diabetes mellitus
1999 · policosanol · Patients with hypercholesterolemia and noninsulin dependent diabetes mellitus
10 mg12 weeks—
Consumption of Cuban Policosanol Improves Blood Pressure and Lipid Profile via Enhancement of HDL Functionality in Healthy Women Subjects: Randomized, Double-Blinded, and Placebo-Controlled Study
2018 · policosanol group · Women aged 18–65 with prehypertension and no known endocrinological disorder
10 mg8 weeks—
Efficacy and Safety of Policosanol Plus Fenofibrate Combination Therapy in Elderly Patients with Mixed Dyslipidemia: A Randomized, Controlled Clinical Study
2018 · policosanol · Patients aged 60 years or older with mixed dyslipidemia
20 mg24 weeks—
Efficacy and Safety of Policosanol Plus Fenofibrate Combination Therapy in Elderly Patients with Mixed Dyslipidemia: A Randomized, Controlled Clinical Study
2018 · fenofibrate + policosanol combination · Patients aged 60 years or older with mixed dyslipidemia
20 mg24 weeks—
Short-Term Consumption of Cuban Policosanol Lowers Aortic and Peripheral Blood Pressure and Ameliorates Serum Lipid Parameters in Healthy Korean Participants: Randomized, Double-Blinded, and Placebo-Controlled Study
2019 · policosanol 10 mg group · Men and women aged 19–65 with prehypertension and no history of endocrinological disorder
10 mg12 weeks—
Short-Term Consumption of Cuban Policosanol Lowers Aortic and Peripheral Blood Pressure and Ameliorates Serum Lipid Parameters in Healthy Korean Participants: Randomized, Double-Blinded, and Placebo-Controlled Study
2019 · policosanol 20 mg group · Men and women aged 19–65 with prehypertension and no history of endocrinological disorder
20 mg12 weeks—
Effects of successive dose increases of policosanol on the lipid profile of patients with type II hypercholesterolaemia and tolerability to treatment
1994 · policosanol, 5 mg twice daily (second 8 weeks) · Patients with type II primary hypercholesterolaemia and elevated serum LDL-C and total cholesterol after a diet-only period
10 mg8 weeks—
Effects of successive dose increases of policosanol on the lipid profile of patients with type II hypercholesterolaemia and tolerability to treatment
1994 · policosanol, 10 mg twice daily (third 8 weeks) · Patients with type II primary hypercholesterolaemia and elevated serum LDL-C and total cholesterol after a diet-only period
20 mg8 weeks—
Concomitant use of policosanol and beta-blockers in older patients
2004 · policosanol · Older hypercholesterolemic patients taking beta-blockers; age range and sex not specified
5 mg3 years98
Comparison of the efficacy, safety and tolerability of original policosanol versus other mixtures of higher aliphatic primary alcohols in patients with type II hypercholesterolemia
2002 · policosanol group, 5 mg/day step · Patients with type II hypercholesterolemia; age and sex not specified
5 mg5 weeks55
Effects of policosanol 20 versus 40 mg/day in the treatment of patients with type II hypercholesterolemia: a 6-month double-blind study
2001 · policosanol 40 mg/day · Patients with type II hypercholesterolemia
40 mg24 weeks30
A comparison of the effects of D-003 and policosanol (5 and 10 mg/day) in patients with type II hypercholesterolemia: a randomized, double-blinded study
2005 · Policosanol 5 mg/day · Patients with type II hypercholesterolemia; age and sex not reported
5 mg8 weeks25
Effects of policosanol in patients with type II hypercholesterolemia and additional coronary risk factors
1999 · Policosanol group, first 12 weeks · Patients with type II hypercholesterolemia and additional coronary risk factors
5 mg12 weeks—
Effects of successive dose increases of policosanol on the lipid profile of patients with type II hypercholesterolaemia and tolerability to treatment
1994 · policosanol, 5 mg once daily (first 8 weeks) · Patients with type II primary hypercholesterolaemia and elevated serum LDL-C and total cholesterol after a diet-only period
5 mg8 weeks—
Multiple functions of policosanol in elderly patients with dyslipidemia
2020 · Group B · Men and women aged 75 years or older with dyslipidemia
10 mg52 weeks72
Multiple functions of policosanol in elderly patients with dyslipidemia
2020 · Group A · Men and women aged 75 years or older with dyslipidemia
20 mg52 weeks64
Multiple functions of policosanol in elderly patients with dyslipidemia
2020 · Group D · Men and women aged 75 years or older with dyslipidemia
10 mg52 weeks62
[Effects of policosanol combined with simvastatin on serum lipids and sex hormones in male patients with hyperlipidemia]
2013 · treatment group · male patients with hyperlipidemia
20 mg16 weeks60
Comparison of the efficacy and tolerability of policosanol with atorvastatin in elderly patients with type II hypercholesterolaemia
2003 · policosanol · Adults aged 60–80 with type II hypercholesterolaemia
10 mg8 weeks38
[Effects of policosanol on serum lipids and heme oxygenase-1 in patients with hyperlipidemia]
2012 · treatment group · Patients with hyperlipidemia; age and sex not stated
20 mg16 weeks36
Long-term therapy with policosanol improves treadmill exercise-ECG testing performance of coronary heart disease patients
1998 · policosanol · coronary heart disease patients with myocardial ischemia; age and sex not reported
10 mg608 days15
Effect of policosanol on platelet aggregation in type II hypercholesterolemic patients
1998 · policosanol · Patients with type II hypercholesterolemia and total cholesterol >5.0 mmol/L despite dietary conditions, receiving step-one cholesterol-lowering therapy
10 mg30 days—
A comparative study of policosanol Versus acipimox in patients with type II hypercholesterolemia
1999 · policosanol · Patients with type II hypercholesterolemia
10 mg8 weeks—
Antiplatelet effects of policosanol (20 and 40 mg/day) in healthy volunteers and dyslipidaemic patients
2002 · policosanol 20 mg/day · healthy volunteers and patients with type II hypercholesterolaemia
20 mg30 days—
Treatment of hypercholesterolemia in NIDDM with policosanol
1995 · policosanol · Adults with non-insulin-dependent diabetes mellitus (NIDDM) and hypercholesterolemia
10 mg12 weeks—
A two-year study on the efficacy and tolerability of policosanol in patients with type II hyperlipoproteinaemia
1995 · Policosanol · Patients of both sexes with type II hyperlipoproteinaemia whose total cholesterol and LDL-C were insufficiently controlled by diet
10 mg2 years—
Effect of policosanol successive dose increases on platelet aggregation in healthy volunteers
1996 · Policosanol 10 mg day-1 · Healthy volunteers
10 mg7 days—
Effect of policosanol successive dose increases on platelet aggregation in healthy volunteers
1996 · Policosanol 20 mg day-1 · Healthy volunteers
20 mg7 days—
Comparative study of policosanol, aspirin and the combination therapy policosanol-aspirin on platelet aggregation in healthy volunteers
1997 · policosanol · healthy volunteers
20 mg7 days—
Comparative study of policosanol, aspirin and the combination therapy policosanol-aspirin on platelet aggregation in healthy volunteers
1997 · combination therapy policosanol-aspirin · healthy volunteers
20 mg7 days—
Nutraceutical pill containing berberine versus ezetimibe on plasma lipid pattern in hypercholesterolemic subjects and its additive effect in patients with familial hypercholesterolemia on stable cholesterol-lowering treatment
2012 · BBR/P/RR monotherapy · Adults with primary polygenic hypercholesterolemia who were statin-intolerant or declined statin treatment
10 mg180 days152
Nutraceutical pill containing berberine versus ezetimibe on plasma lipid pattern in hypercholesterolemic subjects and its additive effect in patients with familial hypercholesterolemia on stable cholesterol-lowering treatment
2012 · Supplementary BBR/P/RR in HeFH patients on stable statin treatment or statin plus ezetimibe · Adults with genotype-confirmed heterozygous familial hypercholesterolemia on stable-dose statins or statins plus ezetimibe
10 mg90 days30
Nutraceutical pill containing berberine versus ezetimibe on plasma lipid pattern in hypercholesterolemic subjects and its additive effect in patients with familial hypercholesterolemia on stable cholesterol-lowering treatment
2012 · Combined BBR/P/RR plus ezetimibe therapy · Adults with primary hypercholesterolemia selected for a low response to monotherapy
10 mg90 days26
Effects of addition of policosanol to omega-3 fatty acid therapy on the lipid profile of patients with type II hypercholesterolaemia
2005 · omega-3 FA + policosanol 5 mg/day · Patients with type II hypercholesterolaemia
5 mg8 weeks—
Effects of addition of policosanol to omega-3 fatty acid therapy on the lipid profile of patients with type II hypercholesterolaemia
2005 · omega-3 FA + policosanol 10 mg/day · Patients with type II hypercholesterolaemia
10 mg8 weeks—
A Randomized, Double-Blinded, Placebo-Controlled, Clinical Study of the Effects of a Nutraceutical Combination (LEVELIP DUO(®)) on LDL Cholesterol Levels and Lipid Pattern in Subjects with Sub-Optimal Blood Cholesterol Levels (NATCOL Study)
2020 · LEVELIP DUO® · Adults aged 30–75 with moderately hypercholesterolemic, sub-optimal blood cholesterol levels, without other cardiovascular risk factors and not taking lipid-lowering drugs
10 mg8 weeks43
Effects of a new combination of nutraceuticals with Morus alba on lipid profile, insulin sensitivity and endotelial function in dyslipidemic subjects. A cross-over, randomized, double-blind trial
2015 · Combination A · Adults aged 18–70 with hypercholesterolemia not requiring statins or statin-intolerant
10 mg4 weeks23
Safety and efficacy of policosanol in patients with high on-treatment platelet reactivity after drug-eluting stent implantation: two-year follow-up results
2016 · group C · Patients with high on-treatment platelet reactivity after drug-eluting stent implantation; age and sex not reported
40 mg26 weeks150
Long-term therapy with policosanol improves treadmill exercise-ECG testing performance of coronary heart disease patients
1998 · policosanol plus aspirin · coronary heart disease patients with myocardial ischemia; age and sex not reported
10 mg608 days15
Antiplatelet effects of policosanol (20 and 40 mg/day) in healthy volunteers and dyslipidaemic patients
2002 · policosanol 40 mg/day · healthy volunteers and patients with type II hypercholesterolaemia
40 mg30 days—
Effect of policosanol successive dose increases on platelet aggregation in healthy volunteers
1996 · Policosanol 40 mg day-1 · Healthy volunteers
40 mg7 days—
Efficacy of a nutraceutical combination on lipid metabolism in patients with metabolic syndrome: a multicenter, double blind, randomized, placebo controlled trial
2019 · Armolipid Plus (AP) · Adults aged 18–70 with metabolic syndrome and left ventricular hypertrophy; men and women
10 mg24 weeks71
Effect of policosanol on hyperlipidemia and coronary heart disease in middle-aged patients. A 14-month pilot study
1996 · policosanol group · Middle-aged outpatients with chronic coronary heart disease and primary or marginal hyperlipidemia
2 mg426 days12
The treatment of hypercholesterolemic children: efficacy and safety of a combination of red yeast rice extract and policosanols
2011 · Dietary supplement · Children aged 8–16 with heterozygous familial hypercholesterolemia or familial combined hyperlipidemia
10 mg8 weeks40
Effects of a nutraceutical combination (berberine, red yeast rice and policosanols) on lipid levels and endothelial function randomized, double-blind, placebo-controlled study
2010 · nutraceutical combination (NC) · Adults with hypercholesterolemia; mean age 55 years; 26 males and 24 females were randomized across both arms
10 mg10 weeks25
Effects of poly-bioactive compounds on lipid profile and body weight in a moderately hypercholesterolemic population with low cardiovascular disease risk: a multicenter randomized trial
2014 · Intervention (Armolipid Plus/AP) · Men and women older than 18 years with mild-moderate hypercholesterolemia and elevated LDL-c, candidates for lifestyle intervention without hypolipemic drug treatment
10 mg12 weeks51
Effects of a New Combination of Medical Food on Endothelial Function and Lipid Profile in Dyslipidemic Subjects: A Pilot Randomized Trial
2019 · Nutraceutical B · Adults aged 18–75 with elevated serum cholesterol not requiring statins or statin-intolerant; people with cardiovascular disease and uncontrolled diabetes were excluded.
10 mg6 weeks23